Principles Of Immunogenicity Assessment Using BiacoreTM T200 SPR System
Source: Cytiva
The assessment of unwanted immunogenicity is a key parameter in the development process of biological protein drugs. Usually, ligand binding technologies such as ELISA are used for early immune responses, whereas SPR technology is utilized for the characterization of antibody isotypes, which may be important for the interpretation of the clinical consequences of unwanted immunogenicity.
VIEW THE WEBINAR!
Log In
Signing up provides unlimited access to:
Free Sign Up

Signing up provides unlimited access to:
- Trend and Leadership Articles
- Case Studies
- Extensive Product Database
- Premium Content
HELLO. PLEASE LOG IN.
X
Not yet a member of BioProcess Online? Register today.
ACCOUNT SIGN UP
X
Please fill in your account details
ACCOUNT SIGN UP
This website uses cookies to ensure you get the best experience on our website. Learn more